Mean change in HbA_1c [%]

-0,37%

-0,42%

-1,53%

-0,22%

-0,42%

-1,67%

-2,00% -1,00% 0,00%

type 1

type 2 basal-bolus

type 2 insulin+OAD

IDet NPH

Mean change in BMI [kg/m2]

-0,2

0,26

0,42

0,06

0,51

0,99

type 1

type 2 basal-

bolus

type 2

insulin+OAD

IDet NPH

Non-specificmortality

No

Yes

No

Yes

Lasertreatment

ACEI

treatment

Statin

treatment

Aspirin

treatment

User sets simulation conditions

Generate baseline population

Any patients to run?

Time horizon reached?

Stop

Screening

Overall annual survival

Time counter advances

Update simulation data

ACEI – Angiotensin converting enzyme inhibitor

Microvascularcomplications

Macrovascularcomplications

Walczak J. , Pawlik D. , Jasińska A. , Garbacka M.. , Kędzior J. , Fundament T. , Malczak I. , Dardziński W. , Nogas G. , Skrzekowska-Baran I. , Czech M.Arcana Institute, Cracow, Poland, Novo Nordisk Pharma Poland, Warsaw, Poland

1 1 1 1 1 1 1 1 1 2 2

1 2

Insulin detemir PacketPublic selling

price (VAT

included) [PLN]

Reimbursement[PLN]

Patient’s co-payment

[PLN]

Reimbursementper

1 i.u. [PLN]

Levemir 5 wkł. 3ml 271,01 267,81 3,20 0,18

Type 1 and type 2 diabetespatients treated with IIT

Proportion of patients withepisodes of severe

hypoglycaemia *

Proportion of patientstreated with IIT,

receiving NPH insulinTarget population

65 800 0,089 95% 65 800 × 95% × 8,9% = about 5,6thousand patients

Total annual cost [PLN] IDet NPH

Type 1 diabetes

Insulin detemir/NPH 1 903,74 792,82

Short-/ rapid-acting insulin 828,42 592,85

Total 2 732,16 1 385,67

Type 2 diabetes (intensive insulin therapy)

Insulin detemir/NPH 2 662,87 1 005,92

Short-/ rapid-acting insulin 1 325,69 782,13

Total 3 988,56 1 788,05

Type 2 diabetes (insulin + oral antidiabetes drugs)

Insulin detemir/NPH 3 303,17 1 114,11

Oral antidiabetes drugs 327,38 327,38

Total 3 630,55 1 441,49